Compare VKTX & VRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VKTX | VRNS |
|---|---|---|
| Founded | 2012 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | 2015 | 2014 |
| Metric | VKTX | VRNS |
|---|---|---|
| Price | $34.04 | $33.66 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 14 | 20 |
| Target Price | ★ $87.07 | $57.55 |
| AVG Volume (30 Days) | ★ 3.3M | 2.0M |
| Earning Date | 02-04-2026 | 02-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | ★ $608,677,000.00 |
| Revenue This Year | N/A | $14.57 |
| Revenue Next Year | N/A | $15.80 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 11.37 |
| 52 Week Low | $18.92 | $30.02 |
| 52 Week High | $43.15 | $63.90 |
| Indicator | VKTX | VRNS |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 46.06 |
| Support Level | $29.54 | $34.06 |
| Resistance Level | $36.00 | $35.89 |
| Average True Range (ATR) | 1.98 | 1.28 |
| MACD | -0.02 | 0.17 |
| Stochastic Oscillator | 59.83 | 45.30 |
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
Varonis Systems is a cybersecurity vendor focused on data privacy and security. The firm is currently undergoing a cloud transition as it weans its on-premises customers over to its cloud products that are delivered as software-as-a-service. The New York-based firm was founded in 2005 and went public in 2014.